SCHEMBL6175374

SCHEMBL6175374

Cc1nnnn1-c1ccc(C(CC2CCCC2)C(=O)O)cc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 13/20 0.38
▸ AKR1C2 P52895 13/20 0.38
▸ NOTUM Q6P988 1/20 0.36
▸ APP P05067 1/20 0.36
▸ PSEN1 P49768 1/20 0.36
▸ PSEN2 P49810 1/20 0.36
▸ APH1B Q8WW43 1/20 0.36
▸ NCSTN Q92542 1/20 0.36
▸ APH1A Q96BI3 1/20 0.36
▸ PSENEN Q9NZ42 1/20 0.36
▸ AKR1B10 O60218 2/20 0.36
▸ AKR1C4 P17516 2/20 0.36
▸ AKR1C1 Q04828 2/20 0.36
▸ SCN9A Q15858 2/20 0.35
▸ SMURF1 Q9HCE7 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6172615 0.90 SMURF1 (0.37) NOTUMAPPSCN9ASMURF1KCNH2
SCHEMBL6175702 0.87 KCNH2 (0.39) AKR1C3AKR1C2APPPSEN1PSEN2
SCHEMBL6185486 0.87 KCNH2 (0.37) AKR1C3AKR1C2APPPSEN1PSEN2
SCHEMBL6175104 0.87 KCNH2 (0.34) NOTUMSCN9ASMURF1KCNH2
SCHEMBL6174485 0.85 KCNH2 (0.39) APPPSEN1PSEN2APH1BNCSTN
SCHEMBL2657371 0.84 KCNH2 (0.38) APPPSEN1PSEN2APH1BNCSTN
SCHEMBL6172662 0.83 KCNH2 (0.56) KCNH2
SCHEMBL2658873 0.82 GCK (0.42) KCNH2
SCHEMBL6176230 0.81 KCNH2 (0.43) LMNAKCNH2
SCHEMBL7613373 0.79 KCNH2 (0.52) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1209362-C Tetrazolyl-phenyl acetamide glucokinase activators HOFFMANN LA ROCHE (CH) 2005-07-06 — — CN disclosed
EP-1311504-B1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 — — EP disclosed
CN-1466584-A Tetrazolyl-phenyl acetamide glucokinase activators - 2004-01-07 — — CN disclosed
US-6441180-B1 TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-08-27 — — US disclosed
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-05-30 — — US disclosed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 — — US disclosed
US-6369232-B1 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-04-09 — — US disclosed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 AKR1C3 1798/4885AKR1C2 744/4885NOTUM 1489/4885
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 AKR1C3 1798/4885AKR1C2 744/4885NOTUM 1489/4885
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators GCKR, GCK, PFKL AKR1C3 1984/4885AKR1C2 855/4885NOTUM 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback